Tanla Platforms shares in focus as board approves Rs 175-crore share buyback at Rs 875 apiece
Tanla Platforms
shares will be in focus on Tuesday after the company announced that its board has approved a
share buyback
proposal worth up to Rs 175 crore.
The company plans to repurchase up to 20 lakh fully paid-up
equity shares
, representing approximately 1.49% of its total equity capital, at a price of Rs 875 per share through the tender offer route.
The buyback offer constitutes 24.81% and 7.78% of the company's paid-up equity share capital and free reserves based on its latest standalone and consolidated financial statements as of March 31, 2025, respectively.
Also Read:
Technical picks: Max Healthcare Institute, 360 ONE among 6 stocks that can rally up to 14% in near term
The buyback will be executed on a proportionate basis for all eligible shareholders and beneficial owners as on the record date, which will be announced later. The company will conduct the process through remote electronic voting and postal ballot to secure shareholder approval via a special resolution.
Also Read:
10 midcap stocks with more than 20 buy Calls: Analysts see up to 25% upside
Tanla Platforms Q4 earning
In the March 2025 quarter, Tanla Platforms reported a 9.9% year-on-year decline in net profit to Rs 117.3 crore, compared with Rs 130.2 crore a year ago. Revenue rose slightly by 1.9% to Rs 1,024.4 crore, while EBITDA increased by the same margin to Rs 163.4 crore.
The
EBITDA margin
remained steady at 16%, indicating no material gain in operational efficiency despite the modest rise in revenue.
Also Read:
These 11 Nifty microcap stocks can rally 55-210% in the next 12 months
Tanla Platforms share price target
According to Trendlyne, the average target price for Tanla Platforms stands at Rs 608, implying a potential downside of around 8% from current levels. Among the three analysts tracking the stock, the consensus rating is 'Buy'.
Technical indicators
show the stock's Relative Strength Index (RSI) at 67.9 — nearing overbought territory. The MACD stands at 31.6 and remains above its centerline and signal line, which is considered a bullish signal.
Tanla Platforms
shares closed 1.3% lower at Rs 656.9 on the BSE in the previous session. The stock has surged 53% over the past three months but is still down over 32% in the past year.
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
18 minutes ago
- Hans India
India pharma market grows 6.9 pc in May, chronic therapies lead
New Delhi: The India pharma market (IPM) grew 6.9 per cent (on-year) in May, driven by strong outperformance in cardiac, respiratory, and anti-diabetes therapies, a report showed on Tuesday. In May, Indian companies grew 6.6 per cent, while MNCs grew 8.4 per cent YoY. Acute therapy growth stood at 5 per cent in May, the second consecutive month of muted YoY growth, according to the report by Motilal Oswal Financial Services Ltd. For the 12 months ending in May, IPM growth was led by price/new launches/volume growth of 4.2 per cent/2.3 per cent/1.1 per cent YoY. As of May, the Indian pharma companies held a majority share of 83 per cent in IPM, with the remaining held by multi-national pharma companies (MNCs). In May, among the top 20 pharma companies, JB Chem (up 11.6 per cent YoY), Glenmark (up 11.8 per cent YoY), and Ajanta (up 10.6 per cent YoY) recorded higher growth rates vs IPM. Ajanta outperformed IPM, led by strong double-digit growth across key therapies like Anti Diabetic/Ophthal. JB Chemicals outperformed IPM, led by a strong show in Cardiac/Ophthal/Anti Parasitic. On a MAT basis, the industry reported 7.6 per cent YoY growth. Chronic therapies witnessed 10 per cent YoY growth, while acute therapies displayed 5 per cent YoY growth in May, said the report. Meanwhile, India's pharmaceutical industry, which has emerged as the largest supplier of affordable generic medicines, is poised to grow at 7.8 per cent year-on-year in April 2025 driven by strong demand and new products, according to experts at India Ratings. The country's pharma sector is now ranked 3rd in volume and 14th in value globally and contributes as much as 20 per cent of the world's supply of medicines. The turnover of the Indian pharma industry touched Rs 4,17,345 crore in 2023-24 growing steadily at over 10 per cent annually for the past five years.
News18
22 minutes ago
- News18
Bollywood Actor Jaideep Ahlawat Buys Another Rs 10 Crore Flat With Wife Jyoti Hooda in Mumbai
Last Updated: Actor Jaideep Ahlawat and his wife Jyoti Hooda bought two apartments in Poorna Apartments, Andheri West, each priced at Rs 10 crore. A month after buying an apartment in Andheri West, actor Jaideep Ahlawat and his wife Jyoti Hooda have purchased another apartment in the same Poorna Apartments (Andheri West), on a different floor. The couple bought the first apartment in May 2025 and the second one in June. Each apartment is priced at Rs 10 crore each, according to property registration documents reviewed by Square Yards. The latest transaction was registered in June 2025. This is the couple's second purchase in the same residential project — Poorna Apartments — within a span of two months. The first apartment was bought in May 2025 for the same value and is located on a different floor in the same residential project. Both apartments have similar configurations and areas. According to the IGR property registration documents reviewed by Square Yards, the value of latest purchased apartment in June 2025 stands at Rs 10 crore. It has a carpet area of 1,950 sqft (nearly 181 sqm) and a built-up area of 217.47 sqm (nearly 2,341 sqft), which is the same as the apartment acquired in May. The deal also includes two car parking spaces. The transaction attracted a stamp duty payment of Rs 60 lakh and registration charges of Rs 30,000. Details of the Previous Transaction Registered in May 2025 According to the IGR property registration documents reviewed by Square Yards, the property purchased in May 2025, also for Rs 10 crore, features a similar carpet area of 1,950 sqft (nearly 181 sqm) and a built-up area of 217.47 sqm (nearly 2,341 sqft). It included a total of four car parking spaces. The transaction incurred a stamp duty payment of Rs 60 lakh and registration charges of Rs 30,000. Strategically positioned between Mumbai's prominent business districts and entertainment zones, Andheri West boasts excellent connectivity through the Western Express Highway, Link Road, SV Road, and the Versova-Andheri-Ghatkopar Metro line. Over the years, Andheri West has evolved into a dynamic commercial and residential destination, featuring a lively blend of modern office complexes, co-working spaces, upscale retail outlets, entertainment centres, and premium residential developments. The area's vibrant atmosphere, coupled with its robust infrastructure and proximity to key commercial hubs, makes it a preferred choice for businesses, celebrities and working professionals. Jaideep Ahlawat is an Indian actor who works in Hindi films and web series. He gained recognition for his roles in the films Raees (2017) and Raazi (2018). In 2020, he starred as a police officer in the streaming series Paatal Lok, for which he received the Filmfare OTT Award for Best Actor in a Drama Series. Most recently, he appeared alongside Saif Ali Khan in the Netflix film Jewel Thief (2025).
Mint
23 minutes ago
- Mint
Shares to buy in short term: Mehta Equities' Riyank suggests BEL, 360 ONE WAM, Mphasis shares in short term
Stock market today: India's key stock indexes slipped on Tuesday as investors took a cautious approach following US President Donald Trump's call for Iranians to leave Tehran amidst ongoing attacks between Israel and Iran, escalating fears of a wider regional conflict. The Nifty 50 declined by 0.20% to 24,895 .30, while the Sensex dropped 0.19% to 81,639.66 as of 11:45 IST. Investors also chose to remain cautious ahead of the US Federal Reserve's interest rate announcement later this week, analysts observed. Analysts pointed out that even though market momentum appears positive, escalating tensions between the US and Iran could pose a significant concern. Riyank Arora suggests three stocks in the short term - BEL (Bharat Electronics Ltd), 360 ONE WAM, and Mphasis. Check out his views on the overall market. Nifty 50 has decisively broken above the key resistance level of 24,900, signaling the continuation of bullish Momentum. This breakout opens up the possibility for further upside towards 25,050 and 25,100 in the short term. Momentum indicators such as RSI are trending positively, suggesting strong market sentiment. On the downside, the previous resistance zone around 24,825 is expected to act as immediate support, cushioning any short-term dips. Sustaining above 24,900 will be crucial for the index to maintain upward traction. Bank Nifty is trading near a crucial resistance zone at 56,000. A breakout and close above this level could trigger fresh buying interest, paving the way for targets at 56,200 and 56,400. However, until a decisive move emerges, volatility may persist. On the downside, key support levels are placed at 55,800 and 55,600, where buyers may step in on any intraday weakness. A directional breakout from the current consolidation zone will set the tone for the next leg of the trend. Riyank Arora recommends these three stocks in the short term - BEL (Bharat Electronics Ltd), 360 ONE WAM, and Mphasis. Buy | CMP: ₹ 404 | Stop Loss: ₹ 395 | Target: ₹ 440 BEL has witnessed strong accumulation and is showing signs of breakout on the daily chart. The stock is trading above key moving averages, and technical indicators like RSI suggest increasing strength. A sustained move above ₹ 405 can accelerate momentum toward ₹ 440. Maintain a stop loss at ₹ 395 to protect against downside volatility. Buy | CMP: ₹ 1,169 | Stop Loss: ₹ 1,100 | Target: ₹ 1,300 360 ONE WAM has resumed its upward trajectory after a brief consolidation phase. The breakout above ₹ 1,150 is supported by rising volumes and a bullish MACD crossover. Momentum indicators favour a continuation of the uptrend towards ₹ 1,300. A protective stop loss at ₹ 1,100 is recommended for short-term positions. Buy | CMP: ₹ 2,707 | Stop Loss: ₹ 2,600 | Target: ₹ 3,100 Mphasis has broken above a multi-session consolidation zone, confirming a bullish breakout. The stock is supported by strong volume activity and a rising RSI, reflecting underlying strength. With tech stocks seeing renewed interest, Mphasis looks poised to rally toward ₹ 3,100. Traders should maintain a stop loss at ₹ 2,600 for effective risk control. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
